UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000028779
Receipt number R000032937
Scientific Title Phase I/II study of HSCT from HLA-matched donor using post-transplant cyclophosphamide
Date of disclosure of the study information 2017/11/01
Last modified on 2024/02/26 10:11:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase I/II study of HSCT from HLA-matched donor using post-transplant cyclophosphamide

Acronym

Tsukuba PTCY for MRD/MUD

Scientific Title

Phase I/II study of HSCT from HLA-matched donor using post-transplant cyclophosphamide

Scientific Title:Acronym

Tsukuba PTCY for MRD/MUD

Region

Japan


Condition

Condition

AML, ALL, NHL. MDS

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate safety and efficacy of HSCT from MRD/MUD using post-transplant cyclophosphamide

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase I,II


Assessment

Primary outcomes

Success rate at 6 months.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

50 mg/kg of cyclophosphamide on day 3, 4

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit

60 years-old >=

Gender

Male and Female

Key inclusion criteria

1) AML, ALL, NHL, MDS
2) age 16-60
3) PS =< 2
4) EF >= 40%
5) SpO2 >= 90%
6) Bil =< 2.0 mg/dl
7) Ccr >= 30 ml/min

Key exclusion criteria

1) positive for HBs Ag
2) positive for HIV Ag
3) depression
4) pregnancy
5) coexisting active cancer
6) active infection

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Chiba
Middle name
Last name Chigeru

Organization

University of Tsukuba

Division name

Department of Hematology, Faculty of Medicine

Zip code

3058575

Address

1-1-1, Tennodai, Tsukuba, Ibaraki

TEL

029-853-3127

Email

schiba-tky@umin.net


Public contact

Name of contact person

1st name Kurita
Middle name
Last name Naok

Organization

University of Tsukuba

Division name

Department of Hematology, Faculty of Medicine

Zip code

3058575

Address

1-1-1, Tennodai, Tsukuba, Ibaraki

TEL

029-853-3127

Homepage URL


Email

kuripon@mvb.biglobe.ne.jp


Sponsor or person

Institute

University of Tsukuba

Institute

Department

Personal name



Funding Source

Organization

University of Tsukuba Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

.

Address

.

Tel

.

Email

.


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 11 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2017 Year 09 Month 10 Day

Date of IRB


Anticipated trial start date

2017 Year 11 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 08 Month 22 Day

Last modified on

2024 Year 02 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032937


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name